Interactions of serum cholesterol with anti-herpesvirus responses affect disease progression in clinically isolated syndromes

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F13%3A10191810" target="_blank" >RIV/00216208:11110/13:10191810 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064165:_____/13:10191810

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.jneuroim.2013.07.010" target="_blank" >http://dx.doi.org/10.1016/j.jneuroim.2013.07.010</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.jneuroim.2013.07.010" target="_blank" >10.1016/j.jneuroim.2013.07.010</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Interactions of serum cholesterol with anti-herpesvirus responses affect disease progression in clinically isolated syndromes

Popis výsledku v původním jazyce

Objectives: To investigate whether anti-herpesvirus antibodies are associated with serum cholesterol profiles in clinically isolated syndromes (CIS). Methods: Pre-treatment serum samples from 118 high-risk CIS patients were analyzed for IgG antibodies against cytomegalovirus (anti-CMV), Epstein Barr virus (EBV) viral capsid antigen (VCA) and EBV nuclear antigen-1 (EBNA-1). A lipid profile consisting of high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) was obtained. Clinical and MRI assessments were obtained at baseline, 6, 12, and 24 months after start of interferon-beta treatment Results: The study included 118 CIS patients (77 females, 41 males, 65.3% female; mean age: 28.1 +/- SD 8.1years). Anti-EBV EBNA-1 antibody levels were associated with LDL-C (p = 0.009) and TC (p = 0.008) levels. Anti-CMV positivity status was associated with reduced time to relapse (p = 0.006) and the greater number of relapses (p = 0.009) i

Název v anglickém jazyce

Interactions of serum cholesterol with anti-herpesvirus responses affect disease progression in clinically isolated syndromes

Popis výsledku anglicky

Objectives: To investigate whether anti-herpesvirus antibodies are associated with serum cholesterol profiles in clinically isolated syndromes (CIS). Methods: Pre-treatment serum samples from 118 high-risk CIS patients were analyzed for IgG antibodies against cytomegalovirus (anti-CMV), Epstein Barr virus (EBV) viral capsid antigen (VCA) and EBV nuclear antigen-1 (EBNA-1). A lipid profile consisting of high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) was obtained. Clinical and MRI assessments were obtained at baseline, 6, 12, and 24 months after start of interferon-beta treatment Results: The study included 118 CIS patients (77 females, 41 males, 65.3% female; mean age: 28.1 +/- SD 8.1years). Anti-EBV EBNA-1 antibody levels were associated with LDL-C (p = 0.009) and TC (p = 0.008) levels. Anti-CMV positivity status was associated with reduced time to relapse (p = 0.006) and the greater number of relapses (p = 0.009) i

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FH - Neurologie, neurochirurgie, neurovědy

OECD FORD obor

—

Projekt

<a href="/cs/project/NT13237" target="_blank" >NT13237: Klinické a paraklinické markery roztroušené sklerózy – korelace se současným stavem pacienta a predikce průběhu nemoci.</a><br>

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Neuroimmunology

ISSN

0165-5728

e-ISSN

—

Svazek periodika

263

Číslo periodika v rámci svazku

1-2

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

7

Strana od-do

121-127

Kód UT WoS článku

000326258200016

EID výsledku v databázi Scopus

—